BiOptic (TWSE:6850)

Executive Summary

BiOptic Inc. is a Taiwan-based medtech company specializing in capillary gel electrophoresis (CGE) instruments, consumables, and PCR reagents for research and clinical diagnostics. Its flagship Qsep series offers high-resolution fragment analysis with automated sample handling, complemented by the portable Qamp mini PCR system. Serving life-science labs, hospitals, and biotech firms worldwide, BiOptic focuses on genomics, molecular diagnostics, and glycan profiling. Listed on the Taiwan Stock Exchange (TWSE:6850), the company has a commercial-stage product portfolio and an employee base of 200–500. With the growing demand for cost-effective genomic analysis tools, BiOptic is well-positioned to capture market share in Asia and beyond, leveraging its proprietary CGE technology. The company's public listing provides financial transparency and access to capital for R&D and commercial expansion.

Upcoming Catalysts (preview)

• H2 2026Launch of next-generation Qsep system with enhanced throughput70% success
• 2027FDA 510(k) clearance for Qsep in clinical diagnostics50% success
• Q3 2026Strategic distribution partnership for US and European markets60% success